Earnings results for Ayala Pharmaceuticals (NASDAQ:AYLA)
Ayala Pharmaceuticals, Inc. is estimated to report earnings on 11/12/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.59.
Ayala Pharmaceuticals last posted its quarterly earnings results on August 13th, 2020. The reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.21. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $0.63 million. Ayala Pharmaceuticals has generated $0.00 earnings per share over the last year. Ayala Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 12th, 2020 based off prior year’s report dates.
Analyst Opinion on Ayala Pharmaceuticals (NASDAQ:AYLA)
4 Wall Street analysts have issued ratings and price targets for Ayala Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.00, predicting that the stock has a possible upside of 109.24%. The high price target for AYLA is $25.00 and the low price target for AYLA is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Ayala Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $24.00, Ayala Pharmaceuticals has a forecasted upside of 109.2% from its current price of $11.47. Ayala Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Ayala Pharmaceuticals (NASDAQ:AYLA)
Ayala Pharmaceuticals does not currently pay a dividend. Ayala Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Ayala Pharmaceuticals (NASDAQ:AYLA)
In the past three months, Ayala Pharmaceuticals insiders have not sold or bought any company stock. Only 20.26% of the stock of Ayala Pharmaceuticals is held by institutions.
Earnings and Valuation of Ayala Pharmaceuticals (NASDAQ:AYLA
Earnings for Ayala Pharmaceuticals are expected to grow in the coming year, from ($3.05) to ($2.62) per share.
More latest stories: here